Novo Nordisk | NVO - Selling And Administration Expenses

Stock Price
50.53
Daily Change
-8.48 -14.37%
Monthly
-8.39%
Yearly
-38.88%
Q1 Forecast
56.42

Novo Nordisk reported DKK2.86B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
Bausch Health Companies USD 795M 99M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Merck USD 2.63B 0 Sep/2025
Novartis USD 3.31B 134M Sep/2025
Novo Nordisk DKK 18.85B 2.74B Jun/2025
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Prestige Brands USD 28.04M 419K Sep/2025
Sanofi EUR 2.75B 455M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
Zoetis USD 579M 29M Sep/2025